Depo-Provera: Nov. 30 Registration Deadline Explained

Depo-Provera Settlement: What the November 30 Registration Deadline Requires

The Depo-Provera meningioma settlement has moved from a June 2026 agreement in principle to an active administrative process with a hard date attached. U.S. District Judge M. Casey Rodgers, who oversees MDL 3140 in the Northern District of Florida, issued an August 10, 2026 order setting November 30, 2026 as the deadline for attorneys to register their cases and appointing BrownGreer as settlement administrator.

LlamaLab covered the settlement when the parties reached their agreement in principle in June; the parties signed the formal Master Settlement Agreement on July 21, 2026. Registration is the next concrete step, and it works differently than a settlement payout application. Here is what it requires, and what happens to the claims that do not clear it.

What "Registering" Actually Means

Registration is not a claimant filling out a form to request payment. It is the mechanism by which a law firm formally identifies which of its Depo-Provera cases will be evaluated under the confidential Master Settlement Agreement, so that BrownGreer can begin the eligibility review.

The Roughly 20% Problem

Not every filed case will clear registration. Pfizer has told the court that statute-of-limitations issues could disqualify more than 1,000 women, and the parties' own 80% eligibility estimate implies a comparable gap. To resolve which cases fall into that group, Judge Rodgers approved three pilot cases specifically to test Pfizer's statute-of-limitations defenses, with a general-causation hearing on those pilot cases set for September 18, 2026 in Pensacola.

For a claimant pushed into the non-settling track, the requirements are materially heavier than registering for the settlement: a sworn plaintiff fact sheet, complete medical records substantiating both exposure and injury, and a personalized expert report addressing alternative causes, not a boilerplate causation opinion. Firms with cases carrying any statute-of-limitations exposure should assume they may need this file built well before a 90-day clock starts running.

Records That Support Both Tracks

Whether a case clears registration cleanly or lands in the non-settling track, the underlying medical proof does not change: injection history, imaging, and pathology remain the foundation of the claim.

Injection history is typically the hardest piece to complete. Depo-Provera is administered quarterly, and claimants often received doses across multiple clinics and providers over years, sometimes at facilities that have since closed. LlamaLab retrieves records in 4 days on average (with 30 to 40% returned same-day on electronic requests) and uses insurance data to surface treatment locations clients don't always remember. Invoices are itemized per case to flow through as recoverable case disbursements on settlement statements.

Settlement administrators sort registered claims by documentation quality, and recent settlements show how wide the resulting payment spread can be.

What Firms Should Do Before November 30

The Bottom Line

The Depo-Provera settlement now has real infrastructure behind it: a signed agreement, an administrator, and a registration deadline. But registering is the start of the claims process, not the end of it, and the roughly 20% of cases Pfizer disputes face a materially harder path if they miss the settlement track. Firms that complete their medical documentation before November 30 put their claimants in the group most likely to see a Q1 2027 payment.

Sources: Law.com: Who Is Eligible, and Who Isn't, for the Depo-Provera Settlement (Aug. 13, 2026), Lawsuit Information Center: Depo-Provera Lawsuit Settlement Updates (Aug. 2026), AboutLawsuits.com: Depo-Provera Settlement Town Hall, N.D. Fla.: MDL 3140 orders, MDL 3140 case management transcript, July 27, 2026 hearing. Case counts and deadlines current as of the sources' most recent reporting.